{"title":"Growth Hormone Research","description":"","products":[{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA growth hormone-releasing hormone (GHRH) analog studied for its effects on GH secretion and visceral adiposity. 10mg liquid vial, third-party verified.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is Tesamorelin?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. It is one of the few GHRH analogs with regulatory-cleared applications (under the brand name Egrifta) and has been the subject of extensive clinical research examining its effects on growth hormone levels, body composition, and metabolic parameters.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTesamorelin was developed by Theratechnologies Inc. and first approved by the FDA in 2010 as Egrifta for a specific clinical application related to lipodystrophy in HIV patients. The compound features a trans-3-hexenoic acid modification on the tyrosine residue, enhancing its stability and biological activity compared to native GHRH. Subsequent research has expanded into broader areas of GH physiology and metabolic science.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"10MG","offer_id":44807957970989,"sku":null,"price":89.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/TESAMORALIN_10mg.png?v=1775603407"},{"product_id":"cjc-1295-ipamorelin-cjc-ipa","title":"CJC-1295 \/ Ipamorelin (CJC\/IPA)","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA combination of two growth hormone secretagogues studied for complementary mechanisms. CJC-1295 extends GH (Growth Hormone) release duration while ipamorelin triggers targeted GH pulses.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is CJC\/Ipamorelin?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCJC-1295\/Ipamorelin combines two growth hormone secretagogues that work through distinct pathways. CJC-1295 is a modified GHRH analog with an extended half-life, designed to sustain elevated GH levels over longer periods. Ipamorelin is a selective GHS-R agonist that stimulates GH release in a pulsatile pattern without significantly affecting cortisol or prolactin levels.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as a long-acting GHRH analog. Its extended half-life results from modifications that increase albumin binding. Ipamorelin was first characterized in the late 1990s by Novo Nordisk researchers, who identified it as one of the most selective growth hormone secretagogues available. The practice of combining the two compounds emerged from clinical research settings where investigators sought to optimize both the amplitude and duration of GH release.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"10MG","offer_id":44807980154925,"sku":null,"price":89.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/CJC_IPA.png?v=1775604391"},{"product_id":"sermorelin","title":"Sermorelin","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA synthetic 29-amino-acid analog of GHRH studied for its effects on pituitary growth hormone secretion. One of the most established GH research peptides.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is Sermorelin?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino-acid human growth hormone-releasing hormone (GHRH). It was one of the first GHRH analogs approved for clinical use (Geref) and remains one of the most well-characterized compounds in GH research. Sermorelin stimulates pituitary GH production through a natural, pulsatile pattern.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSermorelin was developed following the isolation and characterization of human GHRH in 1982 by researchers at the Salk Institute. The 29-amino-acid fragment was found to retain the full biological activity of the 44-amino-acid parent molecule. Sermorelin received regulatory approval in 1997 under the brand name Geref for diagnostic use. Though Geref was later discontinued due to manufacturing issues (not safety concerns), sermorelin remains one of the most extensively studied and well-characterized GHRH analogs in the research literature.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"5MG","offer_id":44808005845037,"sku":null,"price":55.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/Sermorelin.png?v=1775606028"},{"product_id":"ipamorelin","title":"Ipamorelin","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eOne of the most selective growth hormone secretagogues, studied for clean GH release without cortisol or prolactin elevation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is Ipamorelin?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIpamorelin is a synthetic pentapeptide that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R). What distinguishes ipamorelin from other GH secretagogues like GHRP-6 or GHRP-2 is its selectivity—published research demonstrates that ipamorelin stimulates GH release with minimal impact on cortisol, prolactin, or ACTH levels.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIpamorelin was first described by researchers at Novo Nordisk in 1998. The compound emerged from a systematic effort to develop growth hormone secretagogues with improved selectivity profiles. Unlike earlier GH secretagogues (GHRP-6, GHRP-2, hexarelin), ipamorelin was shown to stimulate GH release without significantly activating the hypothalamic-pituitary-adrenal axis or raising appetite-stimulating hormones. This selectivity profile made it a preferred research tool for isolating GH-specific effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"10MG","offer_id":44808010268717,"sku":null,"price":69.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/Ipamorelin.png?v=1775606035"}],"url":"https:\/\/protocolaminos.com\/collections\/growth-hormone-research.oembed","provider":"Protocol Aminos","version":"1.0","type":"link"}